SyntheMed Receives US Patent on Novel Polymer Technology

ISELIN, N.J., July 30 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin
Board: SYMD), a biomaterials company engaged in the development and
commercialization of anti-adhesion products, announced today that it has been
awarded US Patent #7,569,643 pertaining to its bioresorbable reverse thermal
gelation polymer technology. This represents the latest in a series of
patents covering this novel technology and pertains to the application of
these materials in the reduction of post-operative adhesion formation. Dr.
Eli Pines, the Company's Vice President and Chief Scientific Officer stated,
"The novelty of these materials is that they can be delivered to difficult to
access sites in the body as a liquid through a syringe or as a spray and, once
exposed to body temperature, rapidly transition to a resorbable, adherent,
high viscosity gel. Thus, they are ideally suited as anti-adhesion materials
in spine and tendon surgery."

About SyntheMed, Inc.
SyntheMed, Inc. is a biomaterials company engaged in the development and
commercialization of anti-adhesion products. The company is primarily focused
on the commercialization of REPEL-CV(TM) Bioresorbable Adhesion Barrier and
the advancement and expansion of product development programs based on its
proprietary bioresorbable polymer technologies.

Statements in this Press Release that are not statements of historical fact,
constitute "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance, or achievements expressed or implied by such forward-looking
statements. Such risks and uncertainties include but are not limited to (i)
potential adverse developments regarding the company's efforts to obtain and
maintain FDA and other required regulatory approvals; (ii) potential
inability to secure funding as and when needed to support the company's
future activities and (iii) unanticipated delays associated with manufacturing
and marketing activities. Reference is made to the company's Annual Report on
Form 10-KSB for the year ended December 31, 2008 for a description of these,
as well as other, risks and uncertainties.

SOURCE SyntheMed, Inc.

Robert P. Hickey, SyntheMed, Inc., +1-732-404-1117, rphickey@synthemed.com